Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study

References

• Ravandi F. How I treat Philadelphia chromosome-positive acutelymphoblastic leukemia. Blood. 2019;133(2):130–136.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008;14(14):4392–4399.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration FDA Drug Safety Communication. FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales; [cited 2014 June 17]. Available from: http://www.fda.gov/drugs/drugsafety/ucm373040.htm
   Google Scholar
• Abou Dalle I, Kantarjian HM, Short NJ, et al. Ph + ALL in first relapse in the era of TKI inhibitors. Am J Hematol. 2019;94(12):1388–1395.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–1796.
   PubMed Web of Science ®Google Scholar
• Heiblig M, Rea D, Chrétien ML, et al. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Exp Hematol. 2018; 67:41–48.
   PubMed Web of Science ®Google Scholar
• Breccia M, Abruzzese E, Castagnetti F, et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol. 2018;97(9):1577–1580.
   PubMed Web of Science ®Google Scholar
• Couturier MA, Thomas X, Huguet F, et al. Blinatumomab + ponatinib for relapsed Ph1-positive acute lymphoblastic leukemia: the French experience. EHA E-Poster Couturier M. 2019;267247:PS946.
   Google Scholar
• Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in. Eur Leukemia. 2009;23(11):1957–1963.
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–1215.
   PubMed Web of Science ®Google Scholar
• Stemhagen A, Adib D, Lustgarten S, et al. The OMNI Patient Registry: a prospective, observational, non-interventional registry to evaluate vascular safety of ponatinib treatment in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Clin Lymphoma Myeloma Leuk. 2017;17:S309–S310.
   Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.
   PubMed Web of Science ®Google Scholar
• Clappier E, Rathana K, Cayuela JM, et al. Persistent BCR-ABL1 clonal hematopoiesis after blast clearance identifies a CML-like subgroup of patients with Philadelphia chromosome-positive (Ph+) ALL: interim results from the GRAAPH-2014 trial. EHA E-Poster Couturier M. 2018;214483:S1568.
   Google Scholar
• Ravandi F, Jorgensen J, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–1221.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESM0 Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v69–v82.
   PubMed Web of Science ®Google Scholar
• Tachibana T, Koyama S, Taiki Andou T, et al. Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia. Int J Hematol. 2019;109(2):162–168.
   PubMed Web of Science ®Google Scholar
• Mauro M, Lisa J, McGarry LJ, Mo Yang M, et al. Characteristics of ponatinib therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + all) patients in real-world clinical practice compared to the PACE trial. EHA E-Poster Couturier M. 2016;132657:E1108.
   Google Scholar
• Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010;85(3):164–170.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyperCVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014;89(3):282–287.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Larson RA, Kantarjian HM, et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1411–1413.
   PubMed Web of Science ®Google Scholar
• Gambacorti‐Passerini C, Kantarjian HM, Kim DW, et al. Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Medicine (Baltimore). 2016; 90(9): 755–768.
   Google Scholar
• Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774–782.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547–1555.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5(12):e618–e627.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Piciocchi A, Papayannidis C, et al. First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2017;130:99–99.
   Web of Science ®Google Scholar
• Short NJ, Kantarjian H, Pui CH, et al. SOHO state of the art update and next questions: Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(7):439–446.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukaemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. JCO. 2017;35(16):1795–1802.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukaemia. N Engl J Med. 2016;375(8):740–753.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897–901.
   PubMed Web of Science ®Google Scholar
• King AC, Pappacena JJ, Tallman MS, et al. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Res. 2019; 79:27–33.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Holtzman NG, Sausville EA, et al. Relapsed Philadelphia chromosome-positive pre-B-ALL after CD19-directed CAR-T Cell therapy successfully treated with combination of blinatumomab and ponatinib. Acta Haematol. 2019;141(2):107–110.
   PubMed Web of Science ®Google Scholar
• Zhu YM, Wu Z, Tan YP, et al. Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: two case reports. Medicine (Baltimore). 2016;95(51):e5676.
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Riva G, et al. BCR-ABL-specific T-cell therapy in Ph + ALL patients on tyrosine-kinase inhibitors. Blood. 2017;129(5):582–586.
   PubMed Web of Science ®Google Scholar